ADVERSE DRUG-REACTIONS - AN OVERVIEW OF SPECIAL CONSIDERATIONS IN THE MANAGEMENT OF THE ELDERLY PATIENT

被引:34
作者
BRAWN, LA [1 ]
CASTLEDEN, CM [1 ]
机构
[1] LEICESTER GEN HOSP,DEPT MED ELDERLY,LEICESTER LE5 4PW,ENGLAND
关键词
D O I
10.2165/00002018-199005060-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The incidence of adverse drug reactions increases with aging, and the elderly are more likely to suffer serious or fatal reactions. Thus, morbidity and mortality are considerable in old patients, with 15% of those in hospital suffering a reaction, and many admitted as a consequence of one. The greater propensity of older patients for adverse drug reactions largely reflects the prescription of drugs to them, although over-the-counter purchases must also play a part. The elderly take more drugs per se (which is a reflection of multiple pathology), and more drugs with a narrow therapeutic index associated with a high risk of dangerous adverse reactions and drug interactions. They also have a reduced ability to withstand any reactions due to concomitant disease, and an altered pharmacokinetic and -dynamic response which tends to increase drug effects. The recommendation must be to use fewer drugs in older patients, perhaps trying alternative medicine first in nonacute conditions. Starting doses can often be reduced in the elderly, and clinical and therapeutic monitoring of effect is mandatory. The use of diuretics, antihypertensives, anti-Parkinsonian drugs and anticoagulants emphasise these points, and is discussed in detail together with digoxin, analgesics and nonsteroidal anti-inflammatory drugs. Clear guidelines are given for the use of each of these classes of drug. © 1990, Adis International Limited. All rights reserved.
引用
收藏
页码:421 / 435
页数:15
相关论文
共 99 条
[1]  
Ada D.H., Howie A.J., Michal J., McConkey B., Bacon P.A., Et al., Non-steroidal anti-inflammatory drugs and renal failure, Lancet, 1, pp. 57-60, (1986)
[2]  
Ada K.R.H., Al-Hamouz S., Edmund E., Tallis R.G., Vellodi C., Et al., Inappropriate prescribing in the elderly, Journal of the Royal College of Physicians, 21, pp. 39-41, (1987)
[3]  
Antal E.J., Kramer P.A., Mercik S.A., Chapron D.J., Lawson I.R., Theophylline pharmacokinetics in advanced age, British Journal of Clinical Pharmacology, 12, pp. 637-645, (1981)
[4]  
Ashour M., Salama F.D., Morris A., Skinner J., Acute dysphagia induced by bendrofluazide-K, Practitioner, 228, pp. 524-525, (1984)
[5]  
Baillie S.P., Bateman N., Coates P.E., Woodhouse K.W., Age and pharmacokinetics of morphine, Age and Ageing, 18, pp. 258-262, (1989)
[6]  
Blake A.J., Morgan K., Bendall M.J., Dallosso H., Ebrahim S.B.J., Et al., Falls by elderly people at home: prevalence and associated factors, Age and Ageing, 17, pp. 365-372, (1988)
[7]  
Birkmayer W., Birkmayer G.D., Effect of (−) deprenyl in the longterm treatment of Parkinson’s disease. A 10-year experience, Journal of Neurological Transmission, 22, pp. 219-225, (1986)
[8]  
Birtel O., Buhler F.R., Kiowski W., Lutold B., Decreased beta-adrenoreceptor responsiveness as related to age, blood pressure and plasma catecholamines in patients with essential hypertension, Hypertension, 2, pp. 130-138, (1980)
[9]  
Brater D.G., Chennavasin P., Seiwell R., Frusemide in patients with heart failure: shift in dose response curves, Clinical Pharmacology and Therapeutics, 28, pp. 182-186, (1980)
[10]  
Brater D.G., Day B., Burdettle A., Anderson S., Bumetamide and frusemide in heart failure, Kidney International, 26, pp. 183-189, (1984)